Long-term, maintenance MMF monotherapy improves the fibrosis progression in liver transplant recipients with recurrent hepatitis C

Transplant International

Volumn 24, Issue 5, 2011, Pages 461-468

  Manzia, Tommaso Maria ^a,c   Angelico, Roberta ^a   Toti, Luca ^a   Bellini, Maria Irene ^a   Sforza, Daniele ^a   Palmieri, Giampiero ^a   Orlando, Giuseppe ^b   Tariciotti, Laura ^a   Angelico, Mario ^a   Tisone, Giuseppe ^a,c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Fibrosis progression rate; Hepatitis C virus recurrence; Immunosuppression; Liver transplant; Mycophenolate mofetil

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE COURSE; DRUG SUBSTITUTION; DYSPEPSIA; FEMALE; GASTROINTESTINAL DISEASE; GENOTYPE; GRAFT REJECTION; HEPATITIS C; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; LEUKOCYTE COUNT; LEUKOPENIA; LIVER BIOPSY; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; LONG TERM CARE; MALE; METABOLIC DISORDER; MONOTHERAPY; NAUSEA; PRIORITY JOURNAL; RECURRENT INFECTION; RETROSPECTIVE STUDY; SCORING SYSTEM;

AGED; ANTIVIRAL AGENTS; BIOPSY; CASE-CONTROL STUDIES; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FIBROSIS; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79953768508     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2011.01228.x     Document Type: Article

References (35)

1. Berenguer M, Lopez-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J Hepatol 2001; 35: 666.
2. Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C viral infection after liver transplantation. N Engl J Med 1996; 334: 815.
3. Gane EJ. The natural history of recurrent Hepatitis C and what influences this. Liver Transpl 2008; 14: S36.
4. Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32: 673.
5. Sánchez-Fueyo A, Restrepo JC, Quintó L, et al. Impact of recurrence of HCV infection after liver transplantation on the long-term variability of the graft. Transplantation 2002; 73: 56.
6. Berenguer M. What determines the natural history of recurrent hepatitis C after liver transplantation? J Hepatol 2005; 45: 448.
7. Klupp J, Pfitzmann R, Langrehr JM, Neuhaus R. Indications of mycophenolate mofetil in liver transplantation. Transplantation 2005; 80(1 Suppl.): S142.
8. Lipsky JJ. Mycophenolate mofetil. Lancet 1996; 348: 1357.
9. Pfitzmann R, Klupp J, Langher JM, et al. Mycophenolate mofetil for immunosuppression after liver transplantation: a follow up study of 191 patients. Transplantation 2003; 76: 130.
10. Papatheodoridis GV, O'Beirne J, Mistry P, Davidson B, Rolles K, Burroughs AK. Mycophenolate mofetil mono- therapy in stable liver transplant patients with cyclosporine-induced renal impairment: a preliminary report. Transplantation 1999; 68: 155.
11. Koch RO, Graziadei IW, Schulz F, et al. Long-term efficacy and safety of mycophenolate mofetil in liver transplant recipients with calcineurin- inhibitors-induced renal dysfunction. Transpl Int 2004; 17: 518.
12. Hebert MF, Ascher NL, Lake JR, et al. Four-year-follow-up of mycophenolate mofetil for graft rescue in liver allograft recipients. Transplantation 1999; 67: 707.
13. Barkmann A, Nashan B, Schmidt HH, et al. Improvement of acute and chronic renal dysfunction in liver transplant patients after substitution of calcineurin inhibitors by mycophenolate mofetil. Transplantation 2000; 69: 1886.
14. Reich DJ, Clavien PA, Hodge EE, for the MMF Renal Dysfunction after Liver Transplantation Working Group. Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: randomized, prospective, multicenter pilot study results. Transplant 2005; 80: 18.
15. Orlando G, Baiocchi L, Cardillo A, et al. Switch to 1.5 grams MMF monotherapy for CNI-related toxicity in liver transplantation is safe and improves renal function, dyslipidemia, and hypertension. Liver Transpl 2007; 13: 46.
16. Schlitt HJ, Barkmann A, Böker KHW, et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver transplant patients with renal dysfunction: a randomized controlled study. Lancet 2001; 357: 587.
17. Raimondo ML, Dagher L, Papatheodoridis GV, et al. Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Transplantation 2003; 75: 186.
18. Fairbanks KD, Thuluvath PJ. Mycophenolate mofetil monotherapy in liver transplant recipients: a single center experience. Liver Transpl 2004; 10: 1189.
19. Herrero JI, Quiroga J, Sangro B, et al. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil. Liver Transpl 1999; 5: 414.
20. Moreno Planas JM, Cuervas-Mons Martinez V, Rubio Gonzalez E, et al. Mycophenolate mofetil can be used as monotherapy late after liver transplantation. Am J Transpl 2004; 4: 1650.
21. Stewart SF, Hudson M, Talbot D, Manas D, Day CP. Mycophenolate mofetil monotherapy in liver transplantation. Lancet 2001; 357: 609.
22. Pierini A, Mirabella S, Brunati A, Ricchiuti A, Franchello A, Salizzoni M. Mycophenolate mofetil monotherapy in liver transplantation. Transpl Proc 2005; 37: 2614.
23. Roos N, Poulalhon N, Farge D, Madelaine I, Mauviel A, Verrecchia F. In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil. J Pharmacol Exp Ther 2007; 321: 583.
24. Morath C, Schwenger V, Beimler J, et al. Antifibrotic actions of mycophenolic acid. Clin Transplant 2006; 17(Suppl.): S25.
25. Bahra M, Neumann UP, Jacob D, et al. MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: impact on histological course. Am J Transpl 2005; 5: 406.
26. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696.
27. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997; 25: 658.
28. Maluf DG, Edwards EB, Stravitz RT, Kauffman HM. Impact of the donor risk index on the outcome of hepatitis C Virus-positive liver transplantation recipients. Liver Transpl 2009; 15: 592.
29. Terrault NA, Berenguer M. Treating hepatitis C infection in liver transplant recipients. Liver Traspl 2006; 12: 1192.
30. Wiesner RH, Sorrell M, Villamin F. Report of the first international liver transplantation society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003; 9: S1.
31. Amin MG, Wolf MP, TenBrook Jr JA, et al. Expanded criteria donor grafts for deceased donor liver transplantation under the MELD system: a decision analysis. Liver Transpl 2004; 10: 1468.
32. Kornberg A, Kupper B, Wilberg J, et al. Conversion to mycophenolate mofetil for modulating recurrent hepatitis C in liver transplant recipients. Transplant Infections Disease. 2007; 9: 295.
33. Henry SD, Metselaar HJ, Richard CB, et al. Mycophenolic acid inhibits hepatitis c virus replication and acts in synergy with cyclosporin A and interferon-a. Gastroenterology 2006; 131: 1452.
34. Denton MD, Magee CC, Sayegh MH. Immunosuppressive strategies in transplantation. Lancet 1999; 1: 1083.
35. Kamphues C, Bova R, Röcken C, et al. Safety of mycophenolate mofetil monotherapy in patients after liver transplantation. Ann Transplant 2009; 14: 40.